Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma.
Zhi-Ming WangShi-Long ZhangHua YangRong-Yuan ZhuangXi GuoHan-Xing TongYong ZhangWei-Qi LuYu-Hong ZhouPublished in: Cancer medicine (2020)
High-dose anlotinib combined with epirubicin was an effective and safe therapy for STS.